[HTML][HTML] Systematic proteome-wide Mendelian randomization using the human plasma proteome to identify therapeutic targets for lung adenocarcinoma
L Zhang, Y Xiong, J Zhang, Y Feng, A Xu - Journal of Translational …, 2024 - Springer
Background Lung adenocarcinoma (LUAD) is the predominant histological subtype of lung
cancer and the leading cause of cancer-related mortality. Identifying effective drug targets is …
cancer and the leading cause of cancer-related mortality. Identifying effective drug targets is …
Post-transcriptional, post-translational and pharmacological regulation of tissue factor pathway inhibitor
Tissue factor (TF) pathway inhibitor (TFPI) is an endogenous natural anticoagulant that
readily inhibits the extrinsic coagulation initiation complex (TF-FVIIa-Xa) and …
readily inhibits the extrinsic coagulation initiation complex (TF-FVIIa-Xa) and …
[HTML][HTML] Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients
JA Park - Korean journal of pediatrics, 2016 - ncbi.nlm.nih.gov
Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients
with hematologic malignancies or autoimmune disorders. The current treatment options …
with hematologic malignancies or autoimmune disorders. The current treatment options …
Uniparental disomy causes deficiencies of vitamin K‐dependent proteins
MA Dasi, R Gonzalez‐Conejero… - … of Thrombosis and …, 2016 - Wiley Online Library
Essentials Vitamin K‐dependent coagulant factor deficiency (VKCFD) is a rare autosomal
recessive disorder. We describe a case of inherited VKCFD due to uniparental disomy. The …
recessive disorder. We describe a case of inherited VKCFD due to uniparental disomy. The …
[HTML][HTML] A short history of thrombosis and hemostasis: part II (40th year celebratory issue)
EJ Favaloro - Seminars in thrombosis and hemostasis, 2014 - thieme-connect.com
Welcome to a very special issue of Seminars in Thrombosis & Hemostasis, the second of
two-planned issue compilations that revolve around the history of thrombosis and …
two-planned issue compilations that revolve around the history of thrombosis and …
[HTML][HTML] Association of TFPI polymorphisms rs8176592, rs10931292, and rs10153820 with venous thrombosis: a meta-analysis
Y Zhang, A Pang, L Zhao, Q Guo, Z Zhang, X Zhu… - Medicine, 2019 - journals.lww.com
Background: Tissue factor pathway inhibitor (TFPI) polymorphisms are known to be involved
in venous thrombosis; however, any correlation between the TFPI polymorphisms …
in venous thrombosis; however, any correlation between the TFPI polymorphisms …
[PDF][PDF] The Coagulopathy of Extracorporeal Membrane Oxygenation
A Doyle - 2023 - kclpure.kcl.ac.uk
Extracorporeal membrane oxygenation (ECMO) is a supportive therapy for severe cardiac or
respiratory failure associated with high rates of bleeding and thrombosis. Their development …
respiratory failure associated with high rates of bleeding and thrombosis. Their development …
Effects of Melatonin and Luzindole on plasma levels of tissue factor, tissue factor Pathway inhibitor and Von Willebrand factor in rats
N Negrev, Y Nyagolov, A Zarkova… - Scripta Scientifica …, 2015 - journals.mu-varna.bg
Purpose: The purpose of this study was to investigate the effects of melatonin and luzindole,
inhibitor of the melatonin receptors-MT 1 and MT 2, on plasma levels of tissue factor, tissue …
inhibitor of the melatonin receptors-MT 1 and MT 2, on plasma levels of tissue factor, tissue …